J&J science chief Stoffels to retire after decade at the top, adding to C-suite changes

Johnson & Johnson Chief Scientific Officer Paul Stoffels, M.D., is to retire at the end of the year, ending a nine-year stint at the top of the rejuvenated R&D unit and creating more turnover at the top of the Big Pharma.

Stoffels stepped up to the CSO post in 2012, having spent the previous two years working as global head of pharma R&D. The success of Stoffels' time in the roles is quantifiable. From 2009 to 2020, J&J’s pharma sales rose from $22.5 billion to $45.6 billion on the back of the introduction of a clutch of blockbuster drugs such as Darzalex and Imbruvica.